NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of measles, providing potential incentives including tax credits, fee exemptions, and market exclusivity. The designation supports regulatory advancement of NV-387, a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles and is being developed to address rising global outbreaks.
NV-387 is a unique broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. It has also shown effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles. The Orphan Drug Designation is a significant milestone, as it provides incentives to encourage the development of therapies for rare diseases affecting fewer than 200,000 people in the United States.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. The company's lead drug candidate, NV-387, has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is currently focused on advancing NV-387 into Phase II human clinical trials. Another advanced drug candidate is NV-HHV-1 for the treatment of all Herpesvirus infections, including HSV-1 “cold sores,” HSV-2 “genital ulcers,” VZV Shingles, and Chickenpox.
The Orphan Drug Designation could accelerate the development timeline for NV-387, allowing NanoViricides to potentially benefit from FDA assistance in clinical trial design, reduced fees, and seven years of market exclusivity upon approval. For leaders in the business and technology sectors, this development highlights the growing importance of broad-spectrum antiviral agents in addressing emerging viral threats. The designation also underscores the potential for nanomaterials to revolutionize antiviral therapy, offering a platform that can be adapted to multiple viruses.
The rising global measles outbreaks, partly due to declining vaccination rates, create an urgent need for effective treatments. NV-387's broad-spectrum activity positions it as a versatile tool in pandemic preparedness, potentially reducing the impact of future viral outbreaks. The company's progress in clinical trials will be closely watched by investors and industry stakeholders, as success could lead to significant market opportunities.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/uIWWv.
